Themis Medicare Share Price Target 2027, 2028 and 2030: Long Term Analyst Forecast

Themis Medicare at Rs 108.98 is a diversified company whose share price target of Rs 131 for 2027 represents approximately 13 percent upside from the current market price. The Themis Medicare share price target rises to Rs 147 by 2028 and Rs 184 by 2030, implying a 4-year upside of approximately 59 percent from August 2026 levels. Valued at roughly 975x FY26 EPS (₹0.1), with earnings expected to compound near 12% annually before slowing to approximately10%..

The targets are derived from the analyst consensus and forward earnings model based on FY26 financials. This article covers the Themis Medicare share price target 2027, 2028, and 2030 as of August 2026 to help investors evaluate the long-term investment case.

Click Here – Get Free Investment Predictions

Themis Medicare Company Overview

Metric	Details
NSE Ticker	THEMISMED
Sector	Diversified
CMP (10 Aug 2026)	Rs 108.98
Market Cap	Rs 1009 Cr
Themis Medicare Share Price Target 2027	Rs 131 (+13%)
Themis Medicare Share Price Target 2028	Rs 147 (+27%)
Themis Medicare Share Price Target 2030	Rs 184 (+59%)
Bull Case 2030	Rs 236
Bear Case 2030	Rs 138

What most investors miss: Earnings have collapsed to near-breakeven (EPS approximately0.12 vs historical approximately5) pushing PE to an extreme approximately975x – a major recent profitability deterioration, not a growth story at current price

Valued at roughly 975x FY26 EPS (₹0. 1), with earnings expected to compound near 12% annually before slowing to approximately10%. The share price target of Rs 131 for 2027 and Rs 184 for 2030 reflect this earnings trajectory.

Why Is the Themis Medicare Share Price Target Set at Rs 131 for 2027

Core Business Revenue Growth and Market Position

This is the primary driver of the Themis Medicare share price target for 2027 and 2030. Valued at roughly 975x FY26 EPS (₹0.1), with earnings expected to compound near 12% annually before slowing to approximately10%.. Investors tracking this metric quarterly will have the earliest signal of whether the Themis Medicare share price target timeline is on track.

Margin Improvement and Operational Efficiency

The Themis Medicare share price target of Rs 131 for 2027, rising to Rs 184 by 2030, assumes this factor remains intact and compounds through the forecast period. Any deterioration in this dimension would be the earliest warning for the Themis Medicare share price target thesis.

Balance Sheet Quality and Cash Flow Generation

This structural factor underpins the long-term Themis Medicare share price target of Rs 184 by 2030 beyond the near-term 2027 milestone. Its persistence through economic cycles is what differentiates this investment from a purely cyclical trading position.

Management Track Record and Strategic Execution

For the Themis Medicare share price target to materialise, this factor must continue to hold and improve through FY27 to FY31. It provides the margin of safety for the Rs 147 target in 2028 when earnings quality is most clearly visible.

India's Economy Growth Creates Sector-Wide Tailwind for Themis Medicare

India's long-term economic growth trajectory creates a secular tailwind for Themis Medicare's business that amplifies the company-specific earnings compounding embedded in the Themis Medicare share price target 2030 of Rs 184 (+59% from CMP Rs 108.98).

Themis Medicare Share Price Targets 2027, 2028 and 2030

Themis Medicare Share Price Target 2027: Rs 131

The Themis Medicare share price target 2027 is Rs 131, representing approximately 13 percent upside from CMP Rs 108.98. Valued at roughly 975x FY26 EPS (₹0.1), with earnings expected to compound near 12% annually before slowing to approximately10%.. The primary catalyst for achieving the 2027 target is consistent quarterly earnings delivery that validates the analyst model underpinning the Themis Medicare share price target.

Themis Medicare Share Price Target 2028: Rs 147

The Themis Medicare share price target 2028 is Rs 147, implying approximately 27 percent upside from CMP. By FY29, Themis Medicare should have demonstrated through a complete earnings cycle that the forward growth assumptions are sustainable. This two-year validation of the Themis Medicare share price target thesis typically triggers institutional re-rating toward the Rs 147 level.

Themis Medicare Share Price Target 2030: Rs 184

The Themis Medicare share price target 2030 is Rs 184, implying approximately 59 percent upside from CMP and a 4-year CAGR of approximately 14 percent. By FY31, Themis Medicare should be operating as a mature business with a track record of consistent compounding, justifying the target multiple. Always verify data at NSE and BSE before acting on analyst price targets.

Bull Case and Bear Case for Themis Medicare Share Price Target 2030

Bull Case: Rs 236

The bull case Themis Medicare share price target of Rs 236 by 2030 requires earnings growth to exceed the base case projection and the market to re-rate the stock to a higher-than-consensus multiple. Favourable macro conditions, new product or geographic expansion wins, and sustained margin improvement would drive this upside scenario.

Bear Case: Rs 138

The bear case Themis Medicare share price target of Rs 138 by 2030 applies if earnings growth disappoints relative to analyst expectations, competitive pressure intensifies, or a macro slowdown compresses the sector multiple. Even in this scenario, the downside reflects a more conservative earnings assumption rather than a fundamental business failure.

Scenario	Target 2030	Return
Bull Case	Rs 236	+117%
Base Case	Rs 184	+59%
Bear Case	Rs 138	+27%

Key Risks to the Themis Medicare Share Price Target

Earnings Growth Deceleration

Any slowdown in Themis Medicare's core earnings growth below the projected rate would trigger a PE de-rating and delay the Themis Medicare share price target timeline.

Macro and Sector Headwinds

Global or Indian economic slowdown, regulatory changes, or commodity price cycles could negatively impact Themis Medicare's revenues and the Themis Medicare share price target.

Competition and Market Share Pressure

Competitive intensity from existing players or new entrants could force Themis Medicare to reduce prices or increase spending, compressing the Themis Medicare share price target margins.

Premium Valuation Risk

If the current PE multiple is not supported by sustained earnings delivery, a de-rating could set back the Themis Medicare share price target timeline materially.

How to Invest in Themis Medicare

Use the Univest Screener to track Themis Medicare's quarterly earnings, key sector-specific metrics, and analyst upgrades in real time. To purchase shares, open a demat account with any SEBI-registered broker and search for NSE ticker THEMISMED. Review the quarterly earnings data and the risk factors outlined in this article before committing capital. Build positions gradually and align the holding period to the Themis Medicare share price target 2030 timeline of approximately 4 years. Consult a SEBI-registered financial advisor before investing.

Use the Univest Screener to Track This Stock Live

Conclusion

The Themis Medicare share price target of Rs 131 for 2027, Rs 147 for 2028, and Rs 184 for 2030 reflects analyst consensus earnings compounding in the diversified sector. The 4-year upside of approximately 59 percent from CMP Rs 108.98 assumes the business delivers on the growth drivers outlined above and maintains the valuation multiple consistent with sector peers. Always verify financial data at NSE India and BSE before making any investment decision.

Download the Univest iOS App or Univest Android App to track Themis Medicare share price live and get daily stock recommendations.

Frequently Asked Questions on Themis Medicare Share Price Target 2027 2028 and 2030

What is the Themis Medicare share price target for 2027?

Ans. The Themis Medicare share price target for 2027 is Rs 131, representing approximately 13 percent upside from CMP Rs 108.98 as of August 2026. Please verify all data at NSE India before investing.

What is the Themis Medicare share price target for 2030?

Ans. The Themis Medicare share price target for 2030 is Rs 184, implying approximately 59 percent upside from CMP Rs 108.98. This reflects the analyst consensus extrapolated at the projected growth rate. These are estimates, not guaranteed returns.

What is the Themis Medicare share price target for 2028?

Ans. The Themis Medicare share price target for 2028 is Rs 147, implying approximately 27 percent upside from CMP. By 2028, two full years of earnings delivery should validate the analyst model and support a re-rating toward this level.

Is Themis Medicare a good long-term investment?

Ans. Themis Medicare has a defined analyst projection for earnings compounding through FY31 in the diversified sector. Whether it suits your portfolio depends on your risk appetite, investment horizon, and sector allocation. Consult a SEBI-registered financial advisor before investing.

What are the key risks to the Themis Medicare share price target?

Ans. Key risks include sector-specific headwinds such as earnings growth deceleration, macro and sector headwinds, and broader macro slowdowns. Please review the full risks section in this article before investing.

What is the bull case for Themis Medicare share price by 2030?

Ans. The bull case Themis Medicare share price target for 2030 is Rs 236, requiring earnings growth above the base case and a higher PE multiple. This scenario needs favourable execution and sector conditions. These are analyst projections, not guaranteed returns.

What is Themis Medicare's current market cap?

Ans. Themis Medicare has a market cap of approximately Rs 1009 crore as of August 2026 based on the data available. Verify the current market cap at NSE India or BSE before making investment decisions.

How can I invest in Themis Medicare?

Ans. You can buy Themis Medicare shares through any SEBI-registered broker by searching for NSE ticker THEMISMED. Review the fundamentals and risk factors before investing, and consult a SEBI-registered financial advisor for personalised guidance.